Although more than a 50 % reduction in BOS incidence was observed in the ALN-RSV01-treated group as compared to placebo, clinically relevant data narrowly missed statistical significance in the ITTc analysis population ( p = 0.058).
1
0.0580
0.0580
Although more than a 50 % reduction in BOS incidence was observed in the ALN-RSV01-treated group as compared to placebo, clinically relevant data narrowly missed statistical significance in the ITTc analysis population ( p = 0.058).